Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients.

STUDY

OBJECTIVE

To examine our institutional experience with recombinant Factor VIIa (rFVIIa) as a treatment for exsanguinating hemorrhage in critically ill trauma patients.

DESIGN

Retrospective case review.

SETTING

A specialized trauma and critical care hospital, serving as the quaternary referral center for trauma and surgical shock in the state of Maryland.

PATIENTS: All patients with diffuse coagulopathy and impending exsanguination, given rFVIIa in an effort to control life-threatening hemorrhage. Patients were in the intensive care unit (ICU) or operating room (OR) and included both acute admissions and late-stage patients with multiple organ system failure.

INTERVENTIONS: Patients of interest were those that had received rFVIIa.

MEASUREMENTS: Examination of medical records, including pharmacy data, laboratory results, and the institutional trauma registry.

MAIN

RESULTS

Administration of rFVIIa contributed to successful control of hemorrhage in three of five patients. Failure in two patients was mostly likely due to overwhelming shock and acidosis.

CONCLUSIONS

Administration of rFVIIa shows promise in the treatment of exsanguinating hemorrhage. Prospective, controlled clinical trials of this therapy are strongly recommended.